Kite Pharma Inc (KITE) 51.53 $KITE Biotech Selloff Has

New Post Public Reply Private Reply Replies (0) Message Board

Aug 26, 2015 at 11:06 PM

Kite Pharma Inc (KITE) 51.53 $KITE

Biotech Selloff Has No Effect on Cellectis Advances: CEO
at The Street - Wed Aug 26, 10:29AM CDT
The selloff in immunotherapy stocks is purely market-based and does not reflect the stunning advances in the cancer fighting space, said Dr. Andre Choulika, CEO of Cellectis S.A.
BLUE: 129.67 (+4.60), KITE: 51.53 (+1.49), CLLS: 30.54 (+1.85), JUNO: 36.50 (+0.69)

Critical Alerts For Gilead Sciences, Kite Pharma, Valero Energy, Starbucks and Nokia Corporation Released By InvestorsObserver
PR Newswire - Tue Aug 25, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for GILD, KITE, VLO, SBUX and NOK.
SBUX: 53.96 (+2.87), VLO: 58.85 (+1.24), KITE: 51.53 (+1.49), GILD: 106.96 (+4.40), NOK: 6.25 (+0.20)

Biotech Stock Mailbag: Celldex, Bluebird, Kite, Inovio
at The Street - Fri Aug 21, 4:55AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care.
BLUE: 129.67 (+4.60), INO: 6.80 (+0.21), GBT: 40.76 (-2.11), KITE: 51.53 (+1.49), PFE: 32.43 (+1.09), MRK: 54.42 (+3.25), CLDX: 14.36 (+0.39), AZN: 31.13 (+0.85), JUNO: 36.50 (+0.69)

Kite Pharma is Now Oversold (KITE)
MarketNewsVideo.com - Thu Aug 20, 3:55PM CDT
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative...
KITE: 51.53 (+1.49)

The Zacks Analyst Blog Highlights: Omeros, AbbVie, Kite Pharma and Avalanche
Zacks Equity Research - Zacks Investment Research - Thu Aug 20, 8:30AM CDT
The Zacks Analyst Blog Highlights: Omeros, AbbVie, Kite Pharma and Avalanche
KITE: 51.53 (+1.49), AAVL: 10.51 (+0.43), ABBV: 63.14 (+2.43), OMER: 16.25 (-0.32)

Billionaires Are Bailing on These Stocks
Todd Campbell, The Motley Fool - Motley Fool - Thu Aug 20, 6:03AM CDT
Following in the footsteps of legendary investors such as Warren Buffett, George Soros, and Carl Icahn may make sense, given that these three have proved themselves in both good and bad times. Fortunately for us, all three of them file a document...
NOV: 39.03 (+1.68), NFLX: 110.13 (+8.61), PSX: 73.30 (+2.75), EBAY: 26.17 (+0.94), KITE: 51.53 (+1.49), PYPL: 33.17 (+0.47), JUNO: 36.50 (+0.69), AAPL: 109.69 (+5.95)

Kite Reassures Investors, Yet Shares Slip -- What Gives?
Todd Campbell, The Motley Fool - Motley Fool - Wed Aug 19, 12:21PM CDT
Few stocks have been as red-hot in the past year as gene-editing plays such as Kite Pharmaceuticals , a clinical-stage biotech researching immuno-oncology drugs that reengineer a patient's immune system to better battle cancer. Kite's shares have...
KITE: 51.53 (+1.49)

George Soros' Fund Just Abandoned This Promising Cancer-Fighting Technology: Should You?
George Budwell, The Motley Fool - Motley Fool - Wed Aug 19, 12:04PM CDT
Soros Fund Management is one of the most closely-watched investing firms on Wall Street because its namesake and chairman, George Soros, has a proven track record of not only beating the major indices, but essentially crushing them for most of his...
BLCM: 16.68 (+0.40), KITE: 51.53 (+1.49), JUNO: 36.50 (+0.69)

Biotech Stocks Get Burned This Summer, but Fall Might Bring Relief
at The Street - Wed Aug 19, 9:30AM CDT
Speculative biotech stocks that were huge winners for healthcare investors earlier this year are now down significantly from their 52-week highs.
BLUE: 129.67 (+4.60), KITE: 51.53 (+1.49), GILD: 106.96 (+4.40), ONCE: 44.63 (+1.62), CELG: 119.23 (+6.53)

Biotech Stock Roundup: Kite Addresses Patient Death Concerns, Omeros Soars on Data
Arpita Dutt - Zacks Investment Research - Wed Aug 19, 7:33AM CDT
Kite Pharma (KITE) provided an update on KTE-C19 and remains on track to provide data later this year at ASH.
BIIB: 298.25 (+16.51), KITE: 51.53 (+1.49), AMGN: 153.98 (+8.79), AAVL: 10.51 (+0.43), ABBV: 63.14 (+2.43), OMER: 16.25 (-0.32)

Kite Pharma Provides Update, Death Not Related to KTE-C19
Arpita Dutt - Zacks Investment Research - Tue Aug 18, 5:50PM CDT
Kite Pharma (KITE) expects to present top-line data from the phase I part of the study later this year at the annual meeting of ASH.
GILD: 106.96 (+4.40), KITE: 51.53 (+1.49), AMGN: 153.98 (+8.79), REGN: 535.47 (+36.45)

Kite defends lymphoma drug
at Investor's Business Daily - Mon Aug 17, 5:49PM CDT
The biotech acknowledged a patient death in a clinical trial but said that the death wasn't related to its drug candidate. Kite (KITE) shares plunged 9% last Thu. and 3.5% on Fri. on rumor of a patient death in a phase one trial of its candidate...
KITE: 51.53 (+1.49)

Kite Pharma: Trial Patient Death Unrelated To Drug
at Investor's Business Daily - Mon Aug 17, 4:16PM CDT
Biotech Kite Pharma (KITE) acknowledged Monday that a patient in one of its clinical trials died, but said the death was unrelated to its drug candidate. Kite's stock was pounded last week, falling 9% on Thursday and 3.5% on Friday, by a rumor of a...
KITE: 51.53 (+1.49)

Kite Pharma (KITE) Stock Rises, Patient Death Not Related to Treatment Candidate
at The Street - Mon Aug 17, 11:29AM CDT
Kite Pharma (KITE) shares are climbing after the company released a statement saying that the death of a patient in its trial was unrelated to its treatment candidate.
KITE: 51.53 (+1.49)

Why Kite Pharma, Inc.'s Stock Briefly Spiked Today
George Budwell, The Motley Fool - Motley Fool - Mon Aug 17, 11:02AM CDT
What : Shares of Kite Pharma , a clinical-stage oncology and hematology company, saw its shares rise by as much as 11% today on heavier than normal volume. This spike was driven by a clinical update/clarification, where the company informed...
KITE: 51.53 (+1.49)

Kite Pharma Provides Update on KTE-C19 Clinical Trial
GlobeNewswire - Mon Aug 17, 7:00AM CDT
Kite KTE-C19 Trial on Track to Advance to Pivotal Phase 2
KITE: 51.53 (+1.49)

Kite Pharma Down On Death Rumor, Juno Patent Dispute
at Investor's Business Daily - Fri Aug 14, 4:07PM CDT
Biotech stock Kite Pharma (KITE) continued to slide Friday after dropping 9% Thursday, and Cowen & Co. analyst Eric Schmidt thinks he knows why. "Recall that Kite is enrolling six patients in the Phase I portion of KTE-C19's Phase I/II trial in...
KITE: 51.53 (+1.49), JUNO: 36.50 (+0.69)

Kite Pharma to Hold Conference Call to Provide a Corporate Update on Monday, August 17, 2015
GlobeNewswire - Fri Aug 14, 3:30PM CDT
Kite Pharma, Inc. (Kite) (Nasdaq:KITE) today announced that it will host a live conference call on Monday, August 17, 2015, at 9:00am Eastern Time to provide a corporate update.
KITE: 51.53 (+1.49)

Critical Alerts For Tesla Motors, Whole Foods Market, Celgene, Kite Pharma and SanDisk Released By InvestorsObserver
PR Newswire - Thu Aug 13, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for TSLA, WFM, CELG, KITE and SNDK.
WFM: 32.40 (+0.81), TSLA: 224.84 (+4.81), KITE: 51.53 (+1.49), SNDK: 49.51 (+3.40), CELG: 119.23 (+6.53)

Kite Pharma 2Q Loss Wider Than Expected, Pipeline in Focus - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Aug 11, 10:42AM CDT
Kite Pharma, Inc.'s (KITE) second quarter loss was wider-than-expected while revenues were in line with expectations.
BLUE: 129.67 (+4.60), KITE: 51.53 (+1.49), GILD: 106.96 (+4.40), AMGN: 153.98 (+8.79)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

UEG's New Advisory Board: Elevating Patient Voices

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

ASTS Faces a Legal Countdown – Investors Take Note

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Lundbeck's Board Leadership Transitions into New Era

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Tomorrowland's Shanghai Return: An Electri-Lifesaver

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Faith and Resilience in China: The Legacy of the Long March

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

AEVEX Faces 48-Hour Deadline for Investor Class Action

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Antheia Secures $80M for Critical Medicine Onshoring

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...